Provided by Tiger Fintech (Singapore) Pte. Ltd.

VolitionRX

0.7392
-0.0358-4.62%
Post-market: 0.7352-0.0040-0.54%18:42 EDT
Volume:295.42K
Turnover:226.10K
Market Cap:76.15M
PE:-2.77
High:0.7845
Open:0.7728
Low:0.7392
Close:0.7750
Loading ...

BRIEF-VolitionRx Updates Progress Of Nu.Q NETs Test Adoption

Reuters
·
07 May

VolitionRX Limited: Outlines Broad Strategy to Become the 'Nets Company' Worldwide Through Licensing and Updates Progress of Nu.q® Nets Test Adoption

THOMSON REUTERS
·
07 May

VolitionRX Is Maintained at Buy by D. Boral Capital

Dow Jones
·
30 Apr

BRIEF-VolitionRx Ltd May Offer & Sell Shares Of Common Stock Having Offering Price Of Up To $7.5 Mln - SEC Filing

Reuters
·
23 Apr

VolitionRX Signs New Capital Sales Agreement

TIPRANKS
·
23 Apr

VolitionRX Ltd May Offer & Sell Shares of Common Stock Having Offering Price of up to $7.5 Mln Pursuant to Sales Agreement - SEC Filing

THOMSON REUTERS
·
23 Apr

VolitionRX Price Target Maintained With a $2.50/Share by HC Wainwright & Co.

Dow Jones
·
11 Apr

HC Wainwright Initiates VolitionRx With Buy Rating, $2.50 Price Target

MT Newswires Live
·
08 Apr

VolitionRX Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
08 Apr

VolitionRX Ltd (VNRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advances

GuruFocus.com
·
01 Apr

BRIEF-Volitionrx Limited Announces Full Fiscal Year 2024 Financial Results And Business Update

Reuters
·
01 Apr

VolitionRX FY Sales $1.200M Miss $1.796M Estimate

Benzinga
·
01 Apr

VolitionRX Limited Announces Full Fiscal Year 2024 Financial Results and Business Update

THOMSON REUTERS
·
01 Apr

VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update

PR Newswire
·
01 Apr

VolitionRX Is Maintained at Buy by D. Boral Capital

Dow Jones
·
31 Mar

BRIEF-Volition Announces Two Poster Presentations At Esmo's European Lung Cancer Congress 2025

Reuters
·
28 Mar

Volition Announces Two Poster Presentations at Esmo's European Lung Cancer Congress 2025

THOMSON REUTERS
·
28 Mar

Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025

PR Newswire
·
28 Mar

Press Release: Volition to Host Virtual Investor Event on Nu.Q(R) Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025

Dow Jones
·
27 Mar

BRIEF-VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering

Reuters
·
26 Mar